ArticleClinical and experimental medicine2020
Angiopoietin-like protein 2 as a novel marker for patients with primary Sjogren's syndrome-related interstitial lung disease.
Article in Clinical and experimental medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 11 citations in OpenAlex.
- Clinical features, diagnosis, and treatment of primary Sjögren's disease with interstitial lung disease: A narrative review.Frontiers in immunology · 2026Review
- Biomarkers on Fibrotic Lung Diseases Associated with Usual Interstitial Pneumonia.International journal of medical sciences · 2026Review
- Pharmacological mechanism of active components inFrontiers in pharmacology · 2026Article
- Comparison of the effect of iguratimod and hydroxychloroquine on regulatory B cells in the treatment of primary Sjögren's syndrome.Frontiers in medicine · 2025Article
- Serum biomarker-based risk model construction for primary Sjögren's syndrome with interstitial lung disease.Frontiers in molecular biosciences · 2024Article
- Roles of TRIM21/Ro52 in connective tissue disease-associated interstitial lung diseases.Frontiers in immunology · 2024Review
- Injured Endothelial Cell: A Risk Factor for Pulmonary Fibrosis.International journal of molecular sciences · 2023Review
- Circulating Th2 cell reduction and Th1/Th2 imbalance are correlated with primary Sjogren's syndrome-associated interstitial lung disease.Arthritis research & therapy · 2022Article
- Cytokine expression in patients with interstitial lung disease in primary Sjogren's syndrome and its clinical significance.American journal of translational research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Angiopoietin-like protein 2 (Angptl2) plays a key role in chronic inflammation and tissue remodeling. We evaluated whether serum Angptl2 is associated with interstitial lung disease (ILD) in primary Sjogren's syndrome (pSS) patients. A total of 158 consecutive pSS patients and 25 normal healthy controls, which completed lung HRCT, were enrolled in our research. The levels of serum Angptl2 and TGF-β1 were measured by enzyme-linked immunosorbent assay. We investigated the correlation between the activity indexes of pSS-ILD patients and the serum Angptl2 levels. There were 71 of 158 (44.94%) patients interpreted pSS-ILD by radiologists at the initial presentation. The median interquartile range for serum Angptl2 was 16.55 ng/mL (range 10.82-41.07) in pSS patients, compared with 6.05 ng/mL (range 3.53-9.91) in normal healthy controls (P < 0.001). Importantly, differences between Angptl2 levels in pSS-ILD patients and pSS-N-ILD patients were also statistically significant [29.80 ng/mL (range 15.42-54.40), 14.75 ng/mL (range 9.85-40.48), P < 0.001]. A logistic regression analysis suggested that anti-Ro52, serum Angptl2 and DLCO were associated with pSS patients with interstitial lung disease, with aORs and 95% CIs of 2.06 (1.14-7.65), 4.13 (1.25-15.89) and 9.51 (2.10-37.74), respectively. Moreover, anti-Ro52 (r
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.